Scott J. Steele
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Scott J. Steele has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Joan E. Adamo
Clinical & Translational Science Institute, University of Rochester Medical Center, Rochester, NY, USA
2 shared publications Christina M. Jones
Chemical Sciences Division, National Institute of Standards and Technology, Gaithersburg, MD, USA
1 shared publicationDongwen Wang
Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
1 shared publicationErin E. Wilhelm
Program for Regulatory Science & Medicine, Georgetown University, Washington, DC, USA
1 shared publicationF. Owen Fields
Worldwide Safety and Regulatory Strategy, Pfizer Research and Development, Collegeville, PA, USA
1 shared publicationMark S. Lowenthal
Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, MD, USA
1 shared publication
Latest Publications
- Open Access
- 1 October 2018
- Published by Cambridge University Press (CUP) in Journal of Clinical and Translational Science
- Vol. 2 (5) , 295-300
The integration of emerging omics approaches to advance precision medicine: How can regulatory science help?
Building on the recent advances in next-generation sequencing, the integration of genomics, proteomics, metabolomics, and other approaches hold tremendous promise for precision medicine. The approval and adoption of these rapidly advancing technologies and methods presents several regulatory science considerations that need to be addressed. To better understand and address these regulatory science issues, a Clinical and Translational Science Award Working Group convened the Regulatory Science to Advance Precision Medicine Forum. The Forum identified an initial set of regulatory science gaps. The final set of key findings and recommendations provided here address issues related to the lack of standardization of complex tests, preclinical issues, establishing clinical validity and utility, pharmacogenomics considerations, and knowledge gaps.
- 1 October 2018
- Published by Cambridge University Press (CUP) in Journal of Clinical and Translational Science
- Vol. 2 (5) , 295-300
Open AccessThe integration of emerging omics approaches to advance precision medicine: How can regulatory science help?
Building on the recent advances in next-generation sequencing, the integration of genomics, proteomics, metabolomics, and other approaches hold tremendous promise for precision medicine. The approval and adoption of these rapidly advancing technologies and methods presents several regulatory science considerations that need to be addressed. To better understand and address these regulatory science issues, a Clinical and Translational Science Award Working Group convened the Regulatory Science to Advance Precision Medicine Forum. The Forum identified an initial set of regulatory science gaps. The final set of key findings and recommendations provided here address issues related to the lack of standardization of complex tests, preclinical issues, establishing clinical validity and utility, pharmacogenomics considerations, and knowledge gaps.
- 17 June 2015
- Published by Wiley in Clinical and Translational Science
- Vol. 8 (5) , 615-618
Advancing a Vision for Regulatory Science Training
Regulatory science, a complex field which draws on science, law, and policy, is a growing discipline in medical‐related applications. Competencies help define both a discipline and the criteria to measure high‐quality learning experiences. This paper identifies competencies for regulatory science, how they were developed, and broader recommendations to enhance education and training in this burgeoning field, including a multifaceted training approach.
- 17 June 2015
- Published by Wiley in Clinical and Translational Science
- Vol. 8 (5) , 615-618
Advancing a Vision for Regulatory Science Training
Regulatory science, a complex field which draws on science, law, and policy, is a growing discipline in medical‐related applications. Competencies help define both a discipline and the criteria to measure high‐quality learning experiences. This paper identifies competencies for regulatory science, how they were developed, and broader recommendations to enhance education and training in this burgeoning field, including a multifaceted training approach.
- 26 October 2011
- Published by Wiley in Clinical and Translational Science
- Vol. 4 (5) , 328-331
CTSA-IP: A Solution to Identifying and Aggregating Intellectual Property across the NIH Clinical Translational Science Award (CTSA) Consortium of Biomedical Research Institutes
One of the objectives of the Consortium of Institutions with Clinical and Translational Science Awards (CTSAs) is to enhance technology transfer among the CTSAs and with public and private sector partners. Clinical and Translational Sciences Award Intellectual Property (CTSA-IP; http://www.CTSAIP.org) is a web-based, open access IP search tool that aggregates and promotes technologies from member institutions of the National Institutes of Health's (NIH) CTSAs consortium. Its ultimate aim is to stimulate collaborative research activity by encouraging the formation of public-private partnerships with CTSA institutions and the NIH. First launched in 2009, CTSA-IP has grown rapidly and met its first objectives of developing wide member institution participation and site usage. This communication will discuss the strategy employed in the initiative of aggregating IP across institutional boundaries, the promise that lies therein, as well as the challenges encountered and lessons learned in promoting CTSA-wide engagement. Clin Trans Sci 2011; Volume 4: 328-331
- 26 October 2011
- Published by Wiley in Clinical and Translational Science
- Vol. 4 (5) , 328-331
CTSA-IP: A Solution to Identifying and Aggregating Intellectual Property across the NIH Clinical Translational Science Award (CTSA) Consortium of Biomedical Research Institutes
One of the objectives of the Consortium of Institutions with Clinical and Translational Science Awards (CTSAs) is to enhance technology transfer among the CTSAs and with public and private sector partners. Clinical and Translational Sciences Award Intellectual Property (CTSA-IP; http://www.CTSAIP.org) is a web-based, open access IP search tool that aggregates and promotes technologies from member institutions of the National Institutes of Health's (NIH) CTSAs consortium. Its ultimate aim is to stimulate collaborative research activity by encouraging the formation of public-private partnerships with CTSA institutions and the NIH. First launched in 2009, CTSA-IP has grown rapidly and met its first objectives of developing wide member institution participation and site usage. This communication will discuss the strategy employed in the initiative of aggregating IP across institutional boundaries, the promise that lies therein, as well as the challenges encountered and lessons learned in promoting CTSA-wide engagement. Clin Trans Sci 2011; Volume 4: 328-331
- 22 December 2010
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 2 (63) , 63mr5
Working with the CTSA Consortium: What We Bring to the Table
In 2006, the National Institutes of Health (NIH) initiated the Clinical and Translational Science Awards (CTSA) program to establish premier academic sites designed to enhance the efficiency and effectiveness of translational research at the local, regional, and national levels. In February 2010, the NIH sponsored a national CTSA forum on “Promoting Efficient and Effective Collaborations Among Academia, Government, and Industry.” This forum brought together a broad set of stakeholders who were charged with developing a path for promoting such partnerships. One theme, discussed in this meeting report, focused on opportunities and approaches to leverage CTSA institutions as a consortium in fostering public-private partnerships.
- 22 December 2010
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 2 (63) , 63mr5
Working with the CTSA Consortium: What We Bring to the Table
In 2006, the National Institutes of Health (NIH) initiated the Clinical and Translational Science Awards (CTSA) program to establish premier academic sites designed to enhance the efficiency and effectiveness of translational research at the local, regional, and national levels. In February 2010, the NIH sponsored a national CTSA forum on “Promoting Efficient and Effective Collaborations Among Academia, Government, and Industry.” This forum brought together a broad set of stakeholders who were charged with developing a path for promoting such partnerships. One theme, discussed in this meeting report, focused on opportunities and approaches to leverage CTSA institutions as a consortium in fostering public-private partnerships.